Spearmint Tea vs Spironolactone for PCOS: Comparing Two Anti-Androgens

Why Compare a Tea to a Prescription Drug at All?

Spearmint tea and spironolactone are worth setting side by side for one reason: they act on the same target. Both are thought to reduce the effect of androgens at the hair follicle — spearmint by lowering circulating testosterone, spironolactone by blocking the androgen receptor directly — which means a reader dealing with PCOS-related hirsutism or acne genuinely does choose between them, or considers one before the other. That is different from comparing two supplements that work through unrelated mechanisms. This is a real fork, and the honest version of it includes the place where the answer is unflattering to the natural option.

Spearmint tea’s own trial data and spironolactone’s full evidence and safety profile are each covered in depth elsewhere on this site. This article puts the two side by side on the same axes — effect size, timeline, and safety burden — rather than repeating either page’s full detail.

How Much Does Each One Actually Lower Androgen Effects?

Spearmint tea moved a blood testosterone number in a 30-day trial of 42 women; spironolactone moved a clinical hirsutism score by roughly eight points against placebo across a much larger combined trial base. Those are two different kinds of evidence, and the gap between them is the core of this comparison.

The only randomized trial to test spearmint tea specifically in PCOS-related hirsutism found that two cups a day for 30 days lowered free and total testosterone in 42 women, but did not produce a statistically significant change in the objective Ferriman-Gallwey hirsutism score (p=0.12). A second, five-day trial in 21 women — 12 with PCOS, 9 with hirsutism from other causes — found a similar drop in free testosterone but did not measure hirsutism at all. Between them, that is the entire published human evidence for spearmint tea and androgens: two small trials, 63 women, and one hirsutism-score result that came back flat.

Spironolactone’s evidence base is larger and measures the thing spearmint’s trials could not: a change a clinician can actually score. A Cochrane-informed pool of hirsutism trials found spironolactone 100 mg daily reduced Ferriman-Gallwey scores against placebo by a mean difference of −7.69 (95% CI −10.12 to −5.26) — graded low-quality evidence, but a real, measured change on the same scale spearmint’s trial used and did not move. A 2023 meta-analysis that helped inform the current international guideline found anti-androgens as a class improved hirsutism more than metformin (WMD −1.59, 95% CI −3.06 to −0.12), though not more than placebo when metformin was not the comparator — a genuinely mixed picture, but one built on a trial base an order of magnitude larger than spearmint’s.

Neither result should be rounded up. Spironolactone’s number is still graded low-quality by the review that produced it, and a 2026 systematic review searching specifically for PCOS spironolactone trials found only five open-label RCTs, with no significant difference from metformin — so “stronger than spearmint” is not the same claim as “settled.” It is, however, a considerably larger and more direct trial base than two small studies, one of which never scored hirsutism at all.

How Long Before Either One Shows a Visible Change?

Plan on six months for spironolactone and an untested but biologically similar window for spearmint tea — neither acts on hair that has already converted from fine vellus hair to coarse terminal hair, so both are limited by the same hair-growth-cycle biology regardless of mechanism.

Spearmint’s 30-day trial was long enough to move a blood hormone but, by the study’s own conclusion, not long enough for hair to catch up to that change. No published trial has followed spearmint tea and a hirsutism score past 30 days, so there is no trial-based number for when — or whether — a visible change would show up. Based on how long a hair follicle’s growth cycle runs, not on trial data, three to six months of consistent use is the realistic window to judge it by.

Spironolactone has an actual trial answer, and it points the same direction: slow. A large, non-PCOS trial randomized 410 women with acne to spironolactone or placebo and found no significant difference in quality-of-life scores at week 12, but a clear difference by week 24 — 82% reporting improvement on spironolactone versus 63% on placebo. Hirsutism trials pooled in the same Cochrane-informed review ran six to twelve months as a field norm. Judged at six or eight weeks, either option looks like it is doing nothing; that is the trial data, not a failure of the option.

The Safety Comparison, Reported Plainly

This is where the two options stop looking like a close call. Spearmint tea is a food with a mild side-effect profile; spironolactone is a prescription drug that requires monitoring, carries drug interactions, and cannot be used without reliable contraception.

Neither of the two spearmint trials reported a formal side-effect table or a participant leaving the spearmint arm because of an adverse reaction. As a mint tea generally — not a finding specific to either PCOS trial — spearmint can worsen acid reflux in people prone to heartburn, because menthol relaxes the muscle that keeps stomach acid down. That is a genuinely mild profile, and saying so plainly is fair.

What is not fair is treating “mild side effects” and “comparable effectiveness” as the same finding. They are not. Spironolactone’s larger measured effect on hirsutism scoring comes with a safety and monitoring burden spearmint’s trials never had to report, because a tea and a potassium-sparing diuretic are not comparable classes of substance.

Spironolactone is teratogenic — its antiandrogenic mechanism, the same one that treats hirsutism, can feminize the genitals of a male fetus — which is why it is not recommended in pregnancy and why reliable contraception is required for anyone taking it who could conceive. It is also potassium-sparing, and hyperkalemia is the reason prescribers order follow-up bloodwork. In healthy young women without kidney or heart disease, the measured rate is low: 974 women and 1,802 potassium tests found a hyperkalemia rate of 0.72%, statistically indistinguishable from the 0.76% baseline rate in women not taking the drug. A 2024 study following 78 women with PCOS on spironolactone for at least 12 months found 19 of 243 post-exposure potassium readings above range, all classified as mild — and fifteen of those women were also taking an ACE inhibitor or ARB, exactly the combination that raises the risk beyond the baseline figure. An NSAID taken regularly or a potassium supplement raises the same risk through a different route, which is why monitoring matters more, not less, alongside any of those four.

Hyperkalemia is frequently asymptomatic until it isn’t, so knowing the symptomatic phase matters as much as knowing the lab number. When it does cause symptoms, they are muscle weakness, palpitations or an irregular heartbeat, and tingling or numbness — all three easy to write off as tiredness or anxiety, which is exactly why they get missed. Anyone taking spironolactone who notices any of them should treat it as same-day, not next-appointment.

So Which One Should You Choose?

This is not a question this article can answer for you, and it is not a sequence — the evidence does not support treating spearmint as a first step to escalate from if it “doesn’t work.” What each option does and what it costs to use are two separate facts, reported here so you can weigh them against your own situation and discuss the actual decision with a clinician: how significant your hirsutism is, whether you are pregnant or trying to conceive, whether you take an ACE inhibitor, ARB, NSAID, or potassium supplement already, and how you weigh a smaller, harder-to-prove effect against a larger, better-measured one that comes with a monitoring requirement.

Insulin-resistant and lean PCOS phenotypes are not reported separately in either option’s trials, so neither has phenotype-specific evidence to offer here — a gap worth naming rather than papering over. What both mechanisms share is a ceiling: neither shrinks a hair that has already converted to a coarse terminal hair, and the full range of hirsutism treatments, including direct hair removal, covers what actually addresses hair that already exists rather than only what happens next.

Who This Comparison Doesn’t Help

Neither option is a fit for every reason someone reaches for an anti-androgen.

• Severe or rapidly progressing hirsutism. Spearmint’s trial evidence never demonstrated a visible change at all, and even spironolactone’s effect is graded low-quality evidence relative to combined hormonal contraception, which guidelines place ahead of anti-androgens for most people.
• Anyone pregnant, trying to conceive, or breastfeeding. Spironolactone is contraindicated without reliable contraception. Spearmint has no trial-based safety data for this situation either — an untested option is not the same as a safe one.
• Cycle regulation or fertility. Neither compound has been tested for ovulation, cycle length, or fertility outcomes; both address androgen-driven hair symptoms specifically.
• Anyone expecting a fast result from either one. The trial data for both options says six months is the realistic minimum before judging effect, not six weeks.

You may see PCOS written as polyendocrine metabolic ovarian syndrome (PMOS), after a 2026 global consensus of more than 50 organisations renamed it. Same condition, same androgen mechanism behind both options above — only the label changed. This article uses PCOS because that is still what readers search.

For the trial-matched preparation itself rather than the comparison, which spearmint tea brands match the trials checks real products against what Grant 2010 and Akdoğan 2007 actually used. And for the full spearmint tea trial breakdown, including the dose-variability problem with tea as an unstandardised product, the complete data sits on its own page rather than repeated here. Both are part of the supplements and medications section, alongside every other option covered with the same evidence-first standard.

Common questions